All News

Four breast cancer treatments are awaiting FDA decisions, with two due before the end of 2026. Here's what's under review, what the data show and what it means.

T-cell engagers and other cellular therapies could help the immune system recognize and target lung cancer, including small cell lung cancer.

NEJM-published phase 1/2 data show RASONQUE achieved a 42% response rate and 89% disease control in RAS mutant metastatic lung cancer.

In the phase 3 CERVINO trial, etentamig improved response rates and progression-free survival compared with standard therapies in patients with relapsed/refractory multiple myeloma.

Gail Fackler reflected on her husband Jim’s stage 4 small cell lung cancer diagnosis, the uncertainty they faced and the hope they found through a clinical trial.

Dr. Jenni Sheng discussed weight management after breast cancer, when medication may be considered and why survivorship care goes beyond cancer surveillance.

Brynn Forlizzi was just 15 when diagnosed with ovarian cancer. She shares 10 things that helped her navigate treatment while staying connected to her teenage life.

Lung cancer patient and her father, a cancer survivor and caregiver, share how community, hope and self-advocacy helped them through treatment.

The FDA approved six cancer drugs in August 2026, including a landmark pancreatic cancer pill. Here's what each approval means for patients and side effects.

T-cell engagers and antibody-drug conjugates are expanding the SCLC treatment landscape as researchers focus on improving responses and overcoming resistance.

Rob Lowe joins CURE Talks Cancer to share his grandmother's breast cancer journey, including the clinical trial that helped prolong her life after she was twice told to get her affairs in order.

Karyopharm submitted an FDA application seeking accelerated approval for XPOVIO plus ruxolitinib for patients with myelofibrosis.

Tagrisso plus Orpathys improved progression-free survival in patients with EGFR-mutated lung cancer and MET overexpression, SANOVO trial shows.

A cancer survivor reflects on body image, grief and emotional healing 12 years after treatment, and why healing doesn’t have to be perfect to be real.

The A-NEW study found that 42% of breast cancer survivors with slower early weight loss reached the 5% goal after Contrave was added.

FDA approves BESREMi for adults with essential thrombocythemia, offering a new treatment option for people living with this rare blood cancer.

FDA approves Mimrylo (rusfertide) for adults with polycythemia vera, offering a new treatment approach that may reduce the need for frequent blood draws.

After breast cancer treatment ends, survivorship can bring unexpected challenges. One survivor shares how she learned to heal and redefine who she is.

A stage IV kidney cancer survivor shares how 10 years of treatment changed his view of success, uncertainty, fear and finding meaning in everyday life.

Ivonescimab plus chemotherapy improved survival compared with Imfinzi plus chemotherapy in patients with previously untreated advanced biliary tract cancer, according to phase 3 findings.

A breast cancer survivor reflects on managing lymphedema, navigating Dupuytren’s disease and finding perspective when new health challenges arise.

Theresa Gannon’s compassion, leadership and dedication to patients and fellow oncology nurses make her an Extraordinary Healer Award nominee.

Dr. Maria Margarete Karsten discusses how weekly symptom monitoring helped identify changes between visits and what patients told her about using it.

Final phase 1 results showed lasting responses to soquelitinib in some patients with relapsed or refractory T cell lymphoma.

Jim Day was told he had six months to live after a stage 4 melanoma diagnosis. A cancer-fighting virus helped shrink his tumors and gave him hope.

A UCLA study found patients with cancer who used biosimilars paid less out of pocket, and their insurers paid far less, than those on brand-name biologics.

Researchers are studying how genetics and environmental factors may influence lung cancer risk and could help shape the future of screening and treatment.

In the phase 2/3 STAR-TREC trial, 78.5% of patients given long-course chemoradiotherapy kept their rectum at 12 months, versus 60.6% with short-course radiotherapy.